Sandra E. Ghayad - Concepedia

Author

Sandra E. Ghayad

Inserm ORCID

Also Known As

Ghayad, Sandra, S Ghayad, S. Ghayad, S.E. Ghayad, Sandra E Ghayad, Sandra E. Ghayad, Sandra Ghayad, Sandra E. Ghayad

Publications

1.9K

Citations

H-Index

Concepts

All Affiliations

Inserm Université Claude Bernard Lyon 1 Centre de Recherche en Cancérologie de Lyon Centre Léon Bérard Lebanese University

About

Sandra E. Ghayad is an author at Inserm specializing in medicine, cell biology, and cancer biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	861
2	Cell Biology	8	8	816
3	Molecular Biology	2	2	381
4	Health Sciences	1	1	45
5	Natural Sciences	1	1	34

Sandra E. Ghayad

Publications

1.6K

Citations

H-Index

Page 1

	Year	Citations
p53 Acts as a Safeguard of Translational Control by Regulating Fibrillarin and rRNA Methylation in Cancer Virginie Marcel, Sandra E. Ghayad, Stéphane Belin, Cancer Cell Transcriptional RegulationCell RegulationMedicineRrna MethylationMolecular Biology	2013	347
Evidence for rRNA 2′-O-methylation plasticity: Control of intrinsic translational capabilities of human ribosomes Jenny Erales, Virginie Marchand, Baptiste Panthu, Proceedings of the National Academy of Sciences	2017	286
Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways Sandra E. Ghayad, Julie A. Vendrell, Sabrina Ben Larbi, International Journal of Cancer Pi3k InhibitorsSignal TransductionEndocrine Therapy ResistanceSignaling PathwayErbb System	2009	131
ZNF217 Is a Marker of Poor Prognosis in Breast Cancer That Drives Epithelial–Mesenchymal Transition and Invasion Julie A. Vendrell, Aurélie Thollet, Nhan Trung Nguyen, Cancer Research Breast OncologyPathologyCancer BiologyMammary Gland DevelopmentTumor Biology	2012	129
A20/TNFAIP3, a new estrogen-regulated gene that confers tamoxifen resistance in breast cancer cells Julie A. Vendrell, Sandra E. Ghayad, S Ben-Larbi, Oncogene Breast OncologyMedicineBreast Cancer CellsNew Estrogen-regulated GeneBreast Cancer	2007	92
mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene‐expression levels Sandra E. Ghayad, Ivan Bièche, Julie A. Vendrell, Cancer Science	2008	76
Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer Sandra E. Ghayad, Julie A. Vendrell, Ivan Bièche, Journal of Molecular Endocrinology	2008	69
Exosomes derived from embryonal and alveolar rhabdomyosarcoma carry differential miRNA cargo and promote invasion of recipient fibroblasts Sandra E. Ghayad, Ghina Rammal, Farah Ghamloush, Scientific Reports	2016	56
ZNF217 confers resistance to the pro-apoptotic signals of paclitaxel and aberrant expression of Aurora-A in breast cancer cells Thollet Aurélie, Julie A. Vendrell, Léa Payen, Molecular Cancer	2010	51
Molecular characterization of anastrozole resistance in breast cancer: Pivotal role of the Akt/mTOR pathway in the emergence of <i>de novo</i> or acquired resistance and importance of combining the allosteric Akt inhibitor MK‐2206 with an aromatase inhibitor Paul Vilquin, Marie Villedieu, Evelyne Grisard, International Journal of Cancer Breast OncologyMtor Inhibitor RapamycinPharmacotherapyCancer BiologyTumor Biology	2013	45

Page 1